Xalatan Receives Paediatric Indication In Europe

Pfizer announced that Xalatan 0.005% (latanoprost) has been approved by the European Commission for reduction of elevated intraocular pressure (IOP) in the treatment of paediatric patients with elevated intraocular pressure and paediatric glaucoma. L...

Full Story →